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miR-137 Inhibits the Invasion of Melanoma Cells
through Downregulation of Multiple Oncogenic
Target Genes
Chonglin Luo1, Paul W. Tetteh1,7, Patrick R. Merz1, Elke Dickes1, Alia Abukiwan1, Agnes Hotz-Wagenblatt2,
Stefan Holland-Cunz3, Tobias Sinnberg4, Birgit Schittek4, Dirk Schadendorf5, Sven Diederichs6 and
Stefan B. Eichmu¨ller1
MicroRNAs are small noncoding RNAs that regulate gene expression and have important roles in various types of
cancer. Previously, miR-137 was reported to act as a tumor suppressor in different cancers, including malignant
melanoma. In this study, we show that low miR-137 expression is correlated with poor survival in stage IV
melanoma patients. We identified and validated two genes (c-Met and YB1) as direct targets of miR-137 and
confirmed two previously known targets, namely enhancer of zeste homolog 2 (EZH2) and microphthalmia-
associated transcription factor (MITF). Functional studies showed that miR-137 suppressed melanoma cell
invasion through the downregulation of multiple target genes. The decreased invasion caused by miR-137
overexpression could be phenocopied by small interfering RNA knockdown of EZH2, c-Met, or Y box–binding
protein 1 (YB1). Furthermore, miR-137 inhibited melanoma cell migration and proliferation. Finally, miR-137
induced apoptosis in melanoma cell lines and decreased BCL2 levels. In summary, our study confirms that miR-
137 acts as a tumor suppressor in malignant melanoma and reveals that miR-137 regulates multiple targets
including c-Met, YB1, EZH2, and MITF.
Journal of Investigative Dermatology (2013) 133, 768–775; doi:10.1038/jid.2012.357; published online 15 November 2012
INTRODUCTION
Cutaneous melanoma is the most severe form of skin cancer
with still increasing incidence. Early-stage melanoma can be
cured by surgical resection, but late-stage melanoma is
difficult to treat with current therapies. To improve treatment
for melanoma patients, large efforts have been put into the
elucidation of cellular and molecular mechanisms underlying
this disease. So far, the initiation and progression of melanoma
have been associated with a number of signaling pathways,
including Ras/Raf/MEK/ERK signaling, WNT/-catenin signaling,
and PTEN/AKT signaling, and recently microRNAs (miRNAs)
have been implicated as key regulators in these pathways
(Gray-Schopfer et al., 2007; Mueller et al., 2009; Mueller and
Bosserhoff, 2010; Bell and Levy, 2011).
miRNAs belong to a class of small noncoding RNAs that
regulate coding gene expression posttranscriptionally in a
sequence-specific manner (Winter et al., 2009). miRNA
expression has been associated with melanoma progression
(Mueller et al., 2009; Philippidou et al., 2010). Bemis et al.
(2008) reported the first functional study on an miRNA in
melanoma, which demonstrates that miR-137 downregulates
microphthalmia-associated transcription factor (MITF), a master
regulator of melanocyte development and deregulated in
melanoma. Recently, Chen et al. showed that miR-137 sup-
pressed uveal melanoma cell proliferation through down-
regulation of MITF and cyclin-dependent kinase 6 (Chen
et al., 2011b). Several studies have shown that miR-137 may
have tumor-suppressive functions in other cancer types such
as brain tumor, colorectal cancer, head and neck cancer, and
gastric cancer (Silber et al., 2008; Langevin et al., 2011; Liu
et al., 2011; Chen et al., 2011a). Although an anticancer role
of miR-137 is emerging in melanoma, a link between miR-137
and clinical outcome is still lacking, and additional studies are
needed to elucidate the function of miR-137 in melanoma.
Given that a single miRNA may have hundreds of targets
(Fabian et al., 2010), it is important to investigate whether
ORIGINAL ARTICLE
1Division of Translational Immunology (D015), German Cancer Research
Center (DKFZ), Heidelberg, Germany; 2Genomics and Proteomics Core
Facility, Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg,
Germany; 3Department of Surgery, University Hospital Heidelberg,
Heidelberg, Germany; 4Department of Dermatology, University of Tu¨bingen,
Tu¨bingen, Germany; 5Department of Dermatology, University Hospital Essen,
Essen, Germany and 6Helmholtz-University-Group ‘Molecular RNA Biology &
Cancer’, German Cancer Research Center (DKFZ) and Institute of Pathology,
University of Heidelberg, Heidelberg, Germany
Correspondence: Stefan B. Eichmu¨ller or Chonglin Luo, Division of
Translational Immunology (D015), German Cancer Research Center (DKFZ),
INF 280, D-69120 Heidelberg, Germany. E-mail: s.eichmueller@dkfz.de or
c.luo@dkfz.de
7Present address: Hubrecht Institute, Utrecht, The Netherlands.
Received 23 December 2011; revised 18 July 2012; accepted 30 July 2012;
published online 15 November 2012
Abbreviations: EZH2, enhancer of zeste homolog 2; HGF, hepatocyte growth
factor; miRNAs, microRNAs; MITF, microphthalmia-associated transcription
factor; mRNA, messenger RNA; NHEM, normal human epidermal melanocyte;
YB1, Y box–binding protein 1
768 Journal of Investigative Dermatology (2013), Volume 133 & 2013 The Society for Investigative Dermatology
other genes are also regulated by miR-137 and how they
might contribute to the progression of melanoma and clinical
outcome.
In this study, the miR-137 expression was examined in a
panel of melanoma cell lines from stage IV patients with
different survival times. We identified two previously unre-
ported candidate targets, c-Met and Y box–binding protein 1
(YB1) for miR-137, on the basis of a correlation analysis of
miRNA and messenger RNA (mRNA) microarray data. These
genes have been validated as direct targets of miR-137.
Furthermore, miR-137 was shown to regulate invasion, migra-
tion, and proliferation in melanoma cells.
RESULTS
Low miR-137 expression is associated with poor survival in stage
IV melanoma patients
By using a Taqman miRNA assay, we analyzed the miR-137
expression of 10 NHEMs (normal human epidermal melano-
cytes) and 29 melanoma cell lines derived from metastasis of
stage IV melanoma patients, which were divided into two
groups (long survivor and short survivor), on the basis of their
survival times after diagnosis of stage IV melanoma (Table 1).
We found that miR-137 expression was significantly lower in
the short-survivor group than in the long-survivor group
(P¼ 0.031) or in the NHEM group (P¼0.028) (Figure 1a).
miR-137 was downregulated in stage IV melanoma cell lines
compared with NHEMs, although the difference (P¼ 0.095)
did not reach a significant level.
For further analysis, we selected two cell lines (Ma-Mel-79b
and Ma-Mel-86b) from this panel of melanoma cell lines, as
these had low to very low levels of endogenous miR-137
(Figure 1b), were known to show invasive capacity in
transwell matrigel assay, and have been tested to have
aggressive growth in NOD/SCID mice (unpublished data).
miR-137 directly targets c-Met and YB1
miR-137 has been described to regulate MITF expression
levels in melanoma (Bemis et al., 2008). In this study, we
aimed at identifying previously unreported targets of miR-137.
Previous studies have shown that simultaneous profiling
of mRNA and miRNA expression is a powerful strategy to
identify target genes whose mRNA level is altered by miRNA
(Huang et al., 2007). Here, we performed a correlation
analysis between miR-137 expression and mRNA expression
of 17,589 different genes, using available miRNA (unpublished
data) and mRNA microarray data (partially published in Hoek
et al. (2006)) from 34 melanoma cell lines, and compared
this with target predictions by three different algorithms
(Supplementary Table S1 online): TargetScan (Lewis et al.,
2003), PicTar (Krek et al., 2005), and Miranda (John et al.,
2004). The correlation analysis included the above-mentioned
29 cell lines from stage IV patients, an additional cell line from
one of these patients, and four cell lines from stage III patients.
We found that the miR-137 expression was negatively
correlated with the mRNA expression of a number of genes,
including c-Met and YB1 (Figure 2a), which were selected for
further analysis because of their involvement in melanoma
progression. All three algorithms predicted the same binding
site within the 30 untranslated region (UTR) of YB1 (position
66–72), and Miranda predicted a binding site within the c-Met
30 UTR (position 843–849) (Figure 2b).
To test whether miR-137 directly targets c-Met and YB1
through their 30 UTRs, dual luciferase assays were performed
using reporter plasmids containing the respective full-length 30
UTRs. Luciferase activities were decreased to 66 and 48%,
respectively, when HEK293 cells were cotransfected with
miR-137 and the corresponding reporter plasmid for c-Met
and YB1 (Figure 2c). Site-specific mutagenesis could
validate the miR-137-binding sites within the 30 UTRs of
c-Met (position 843–849) and YB1 (position 66–72; see
Figure 2b).
To further evaluate whether miR-137 downregulates c-Met
and YB1 at the protein or mRNA level or both, we performed
western blot analysis and Taqman real-time reverse trans-
criptase–PCR to detect the protein and mRNA expression of
the two genes in Ma-Mel-79b and -86b cells transfected with
miR-137 mimics or control mimics. As shown in Figure 3, the
overexpression of miR-137 decreased the protein and mRNA
expression of YB1 in both cell lines compared with the
negative control. miR-137 reduced c-Met protein expression
Table 1. Grouping of melanoma cell lines and patients’
information
Factors Long-survival group Short-survival group
Total number 15 14
Age (mean±SD) 53.4±12.0 y 53.9±14.8 y
Gender (male/female) 9/6 7/7
Stage IV 15 14
Survival (min./mean/max.) 25.4/53.3/
146.7 months
3.1/6.2/10.0 months
17.5
a bP = 0.095
P = 0.028*
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Figure 1. The expression of miR-137 in normal human epidermal
melanocytes (NHEMs) and melanoma cell lines. miR-137 expression was
analyzed by real-time reverse transcriptase–PCR and normalized to RNU6B.
(a) Ten NHEMs and 29 melanoma cell lines established from metastases of
stage IV patients with long survival (n¼15) or short survival (n¼14). Student’s
t-test was applied to compare the differences between groups. *Po0.05.
(b) Endogenous miR-137 expression levels in Ma-Mel-79b and -86b cells.
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in both cell lines, although c-Met mRNA expression was
reduced only in Ma-Mel-79b. Thus, miR-137 directly targets
c-Met and YB1 and decreases mRNA and protein levels.
A few target genes of miR-137 have been previously
reported: MITF, cyclin-dependent kinase 6, and C-terminal-
binding protein 1 in cutaneous or uveal melanoma (Bemis
et al., 2008; Chen et al., 2011b; Deng et al., 2011);
mindbomb homolog 1 (Mib1) in mouse embryonic neurons
(Smrt et al., 2010); enhancer of zeste homolog 2 (EZH2) in
mouse adult neuronal stem cells (Szulwach et al., 2010); and
cell division cycle 42 (CDC42) in colorectal cancer (Liu et al.,
2011). In this study, we also included MITF and EZH2: MITF
is an important transcription factor associated with the
melanoma cell growth and survival; EZH2 expression was
associated with the aggressiveness of cutaneous melanoma
(Bachmann et al., 2006). Indeed, western blot analysis showed
that both MITF and EZH2 proteins were decreased upon miR-
137 transfection in both Ma-Mel-79b and -86b cells
(Figure 3a). Moreover, the overexpression of miR-137 also
downregulated B-cell CLL/lymphoma 2 (BCL2), a downstream
target of MITF, in both cell lines (Figure 3a). miR-137 inhibitor
experiments showed a slight, but significant, upregulation of
c-Met and MITF, but not of YB1 and EZH2, in Ma-Mel-79b
(Supplementary Figure S1 online), possibly because of a low
endogenous miR-137 level.
Thus, we identified two previously unreported direct targets
(c-Met and YB1) and confirmed two previously reported
targets (MITF and EZH2) to be regulated by miR-137 in
melanoma.
miR-137 inhibits invasion of melanoma cells through multiple
targets
We performed a transwell invasion assay to analyze the effect
of miR-137 on the invasive behavior of two melanoma cell
lines (Ma-Mel-79b and -86b). To validate the importance of
the individual miR-137 targets, we also tested whether knock-
down of the selected target genes by small interfering RNA
(siRNA) could phenocopy the effect of miR-137 overexpres-
sion on melanoma cell invasion. Figure 3 shows that the
protein levels of target genes were decreased by siRNA,
except c-Met in Ma-Mel-86b. When fetal calf serum was used
as a chemoattractant (Figure 4a), transfection of miR-137
mimic and siRNAs against YB1, EZH2, and MITF significantly
inhibited the invasive capacity of both Ma-Mel-79b and -86b
cells, whereas transfection of siRNA against c-Met did not
(Figure 4b). Notably, such an inhibitory effect on cell invasion
was much stronger in Ma-Mel-86b cells compared with
Ma-Mel-79b cells, which might be explained by the much
lower endogenous miR-137 level in Ma-Mel-86b cells than in
Ma-Mel-79b cells (cf. Figure 1b). When using fetal calf serum
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Figure 2. miR-137 is negatively correlated with target gene expression and directly targets c-Met and Y box–binding protein 1 (YB1). (a) The expression of
miR-137 and three target genes was negatively correlated. Pearson’s correlation coefficients (r) and P-values were calculated. (b) Schematic presentation
of the positions of predicted miR-137 wild-type (wt) and mutated (mut) target sites in YB1 and c-Met 30 UTRs. (c) Dual luciferase reporter assays prove miR-137-
mediated target repression. HEK293 cells were cotransfected with luciferase constructs possessing wt or mut miR-137-binding sites and a miR-137 or control
mimic. Results are given as the ratio of luciferase activity of miR-137/negative control mimic normalized to empty vector control. Data summarize three
independent experiments and are given as mean±SD. *Po0.05, **Po0.01. MITF, microphthalmia-associated transcription factor; Neg., negative; UTR,
untranslated region.
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plus HGF (hepatocyte growth factor) as chemoattractants,
knockdown of c-Met strongly reduced the invasive activity
of Ma-Mel-79b cells. This is concordant with the notion that
HGF is the only known endogenous ligand of c-Met (Tolbert
et al., 2010), and most melanoma cells can produce HGF that
can activate c-Met in an autocrine manner (Li et al., 2001).
On the contrary, knockdown of c-Met failed to inhibit the
invasion of Ma-Mel-86b cells (Figure 4b) probably because
of the fact that the endogenous expression of c-Met in
Ma-Mel-86b cells was very low and further reduction did
not lead to any effect.
To compensate for possible proliferative effects on the
outcome of our invasion assay, we repeated the transwell
assay and counted invaded and noninvaded cells after 24 or
48 hours (Supplementary Figure S2 online). Except for siRNA
against MITF, the results could be confirmed.
Taken together, miR-137 suppressed melanoma cell inva-
sion, which could be phenocopied by knockdown of each of
the target genes c-Met, YB1, and EZH2.
miR-137 inhibits migration of melanoma cells
To test the effect of miR-137 on the migration of melanoma
cells, we performed wound healing migration assays with Ma-
Mel-79b and -86b cells. As shown in Supplementary Figure S3
online, the overexpression of miR-137 significantly decreased
the migratory activities of Ma-Mel-79b and -86b by 36 and
75%, respectively. The migration of both cell lines was sup-
pressed significantly when YB1 and EZH2 were knocked
down using siRNA. Knockdown of MITF also inhibited the
migration, but the difference did not reach a significant level.
However, knockdown of c-Met was unable to affect the
migratory activity of either cell line. Thus, miR-137 inhibits
the migration of melanoma cells most likely through the
downregulation of YB1 and EZH2.
miR-137 suppresses the proliferation of melanoma cells
To test whether miR-137 might affect the proliferation of
melanoma cells, we performed proliferation assays for Ma-
Mel-79b and -86b cells that were transfected with a miR-137
mimic or a negative control mimic. The proliferation of
Ma-Mel-79b and -86b cells was suppressed by miR-137 at
96 hours and 72 hours after transfection, respectively (Figure 5).
siRNA-mediated knockdown of MITF or EZH2, but not of
c-Met or YB1, inhibited Ma-Mel-79b proliferation. Knock-
down of MITF, c-Met, or YB1, but not of EZH2, inhibited
Ma-Mel-86b proliferation. Hence, the downregulation of
MITF, c-Met, YB1, and EZH2 by miR-137 contributes to the
inhibition of melanoma cell proliferation, but the impact of
each target may vary in different cell lines.
miR-137 induces apoptosis of melanoma cells
To evaluate whether miR-137 induces apoptosis in melanoma,
we performed western blot analysis to analyze the cleavage of
poly-(ADP-ribose) polymerase, which is one of the cleavage
targets of caspase-3 and serves as a marker of apoptotic cells
(Oliver et al., 1998). We found that the 89-kDa cleaved poly-
(ADP-ribose) polymerase was strongly increased after
transfection of miR-137 in both Ma-Mel-79b and -86b cell
lines (Figure 3a). Furthermore, the overexpression of miR-137
caused a decrease of the anti-apoptotic protein BCL2 in both
cell lines (Figure 3a), probably through the downregulation of
MITF. This indicates that the intrinsic apoptosis pathway is
activated by miR-137.
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Figure 3. The regulation of target gene expression by miR-137. (a) Western
blot analysis of Ma-Mel-79b and -86b cells transfected with miR-137 or
negative control mimics, or with small interfering RNAs after 72 hours.
Numbers indicate densitometric quantifications normalized to b-actin and
negative control. (b) Real-time PCR quantification of microphthalmia-
associated transcription factor (MITF), c-Met, and Y box–binding protein 1
(YB1) messenger RNA (mRNA) levels after transfection with miR-137 or control
mimic. Data were normalized to negative controls and are shown as
mean±SD of triplicates. Neg., negative; PARP, poly-(ADP-ribose) polymerase.
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DISCUSSION
Generally, stage IV melanoma patients have a very poor
prognosis, with median survival of 6–10 months and a 5-year
survival rate of o5% (Tsao et al., 2004). The survival of
individual patients can vary from months to years, but the
molecular mechanism underlying this broad range is unknown
so far. In the past decade, miRNAs have been recognized as
important factors in cancer, including melanoma. Since the
first paper on miR-137 and its target MITF in melanoma was
published in 2008 (Bemis et al., 2008), there has been an
increasing interest in the role of miR-137 in the development
and progression of different tumor entities. Several targets of
miR-137 have been identified in various types of cancer,
which indicates a tumor-suppressive function for miR-137
(Silber et al., 2008; Langevin et al., 2011; Chen et al., 2011a;
Liu et al., 2011).
The current study correlates miR-137 expression with
melanoma patients’ outcome. We found that the reduction
of miR-137 expression was associated with short survival in
stage IV melanoma patients. This is in line with previous
reports showing that miR-137 acts as a tumor suppressor
(Chen et al., 2011b). Our findings show that miR-137 executes
its tumor-suppressive functions by targeting multiple onco-
genes. Thus, downregulation of miR-137 may contribute to
the increased aggressiveness of melanoma cells in stage IV
patients. The expression analysis has been carried out on cell
lines without corresponding tumor samples being available.
Further confirmative analysis in tumor specimens is warranted
in the future.
Although miRNAs were initially reported to often repress
the translation of target genes without affecting their mRNA
level (Seggerson et al., 2002), subsequent studies showed that
they may also induce mRNA degradation (Lim et al., 2005),
making global mRNA profiling data useful for screening
miRNA targets (Huang et al., 2007). In this study, a negative
correlation between numerous mRNAs and miR-137 has been
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Figure 4. miR-137 inhibits invasion of melanoma cells through the downregulation of multiple target genes. Ma-Mel-79b and -86b cells were transfected
with microRNA mimic or small interfering RNA (siRNA), and subjected to matrigel invasion assays. (a) Fetal calf serum (FCS) served as a chemoattractant,
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chemoattractants, and invasive cells were stained at 24 hours after seeding. Results shown are representatives of at least two independent experiments performed
in duplicate. Data are presented as mean±SD of 12 fields. *Po0.05, **Po0.01. Bar¼ 100mm. EZH2, enhancer of zeste homolog 2; MITF, microphthalmia-
associated transcription factor; Neg., negative; YB1, Y box–binding protein 1.
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found. Notably, MITF and its downstream targets, such as
SILV, CDK2, GPR143, MLANA, DCT, and TYR (Cheli et al.,
2010), were among the most significantly downregulated
genes (data not shown), which was concordant with the
previous report that MITF is a direct target of miR-137
(Bemis et al., 2008). We selected c-Met and YB1 as
candidate targets of miR-137, because they are involved in
the malignancy of melanoma and have not been reported to
be direct targets of miR-137 so far. Our luciferase reporter
assays showed direct interactions between miR-137 and the 30
UTRs of the two candidates. Furthermore, mRNA and protein
downregulation upon miR-137 overexpression in two
melanoma cell lines was confirmed by real-time reverse
transcriptase–PCR and western blot analysis.
Interestingly, several reports have shown that c-Met is
regulated by MITF (McGill et al., 2006; Beuret et al., 2007;
Mascarenhas et al., 2010). A recent study found that trans-
fection of miR-137 into uveal melanoma cells decreased
c-Met expression through the downregulation of MITF (Chen
et al., 2011b). In fact, we detected decreased expression of
c-Met protein in Ma-Mel-86b cells treated with siRNA against
MITF (Figure 3a), which indicates that MITF might mediate the
downregulation of c-Met protein expression by miR-137 in
this cell line. Moreover, our reporter assay including site
mutagenesis showed direct interaction between miR-137 and
c-Met 30 UTR. It is noteworthy that MITF was found to bind
not only c-Met but also YB1 promoter in 501Mel melanoma
cell line using ChIP-Seq (Strub et al., 2011). However, the
expression of YB1 protein was not downregulated in either
Ma-Mel-79b or -86b cell lines treated with siRNA against
MITF (Figure 3a), indicating that the downregulation of YB1
protein expression by miR-137 was not indirectly mediated by
MITF. Altogether, we identified and validated c-Met and YB1
as previously unreported direct targets of miR-137, and also
confirmed the previously reported targets (MITF and EZH2) of
miR-137 (Bemis et al., 2008; Szulwach et al., 2010).
In the progression of melanoma, invasion is a prerequisite
for tumor metastasis (Miller and Mihm, 2006). Notably, all the
miR-137 targets tested in our study are associated with the
invasion of tumor cells. c-Met is overexpressed or mutationally
activated in a variety of solid tumors (Liu et al., 2008). The
majority of melanoma cells, but not melanocytes, can produce
HGF that induces continuous activation of c-Met, leading to
the downregulation of E-cadherin and invasive growth (Li
et al., 2001). YB1 acts as a transcriptional and translational
factor (Kohno et al., 2003), which is upregulated in melanoma
and involved in proliferation, survival, invasion, and
chemosensitivity of melanoma cells (Schittek et al., 2007).
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Figure 5. miR-137 inhibits melanoma cell proliferation. Ma-Mel-79b and -86b cells were transfected with miR-137 mimic (upper), small interfering RNAs
(siRNAs) against target genes (lower), or corresponding negative controls. Cell viability was measured by WST-1 assay every 24 hours up to 96 hours after
transfection. Results shown are representatives of two independent experiments. Data were normalized to negative control at 24 hours and are presented as
mean±SD of triplicates. *Po0.05, **Po0.01. EZH2, enhancer of zeste homolog 2; MITF, microphthalmia-associated transcription factor; Neg., negative; YB1,
Y box–binding protein 1.
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EZH2 is a polycomb group protein involved in cell cycle
progression, as well as in tumor invasion and metastasis
(Tonini et al., 2008). The overexpression of EZH2 has been
associated with the aggressiveness of the melanoma
(Bachmann et al., 2006).
MITF has been reported to be a lineage-specific oncogene
prone to amplification in melanoma and is critical in mela-
noma cell proliferation and survival (Garraway et al., 2005;
Levy et al., 2006; Dynek et al., 2008). Consistent with
these publications, we observed an antiproliferative effect of
MITF siRNA. Our invasion assays showed no significant
effects by MITF siRNA on invasion when corrected for
proliferative changes. In contrast, other studies showed that
decreased expression of MITF could increase the invasion
of melanoma cells and proposed the so-called rheostat
model defining three different phenotypes in melanoma
cells (Carreira et al., 2006; Hoek et al., 2008): differentiated,
proliferative, and invasive. Strub et al. (2011) have extended
this model and found that very low expression of MITF is
driving the cells into senescence, which might also be the
case with our Ma-Mel-86b cells because of a very strong
downregulation of MITF after siRNA application. Given that
MITF is a transcriptional factor regulating many genes (Cheli
et al., 2010), it may well be that knockdown of MITF leads
to a dysregulation of several downstream genes involved in
invasion.
Malignant melanoma is notorious for its high resistance to
current therapeutic drugs. One of the underlying mechanisms
is the impairment of the apoptosis pathway (Soengas and
Lowe, 2003). Melanoma cells are malignantly transformed
melanocytes, the natural UV protectors of the skin, which
shield neighboring keratinocytes from radiation by transferring
melanin through melanosomes (Soengas and Lowe, 2003).
The enhanced survival feature of melanoma cells may derive
from their cell of origin, the melanocytes, and could be
fostered by additional alterations acquired during tumor
progression (Soengas and Lowe, 2003). Interestingly, several
miR-137 target genes (MITF, c-Met, and YB1) tested in the
present study are associated with melanoma cell survival
(Levy et al., 2006; Puri et al., 2007; Schittek et al., 2007).
BCL2, a key anti-apoptotic factor and downstream target
of MITF (Garraway et al., 2005), is also downregulated by
miR-137. Our study shows that the overexpression of miR-137
in melanoma cells induces apoptosis, and thus might sensitize
melanoma cells to chemotherapeutic agents.
In summary, we propose that miR-137 functions as a tumor
suppressor in malignant melanoma: miR-137 overexpression
inhibits invasion, migration, and proliferation of melanoma
cells. miR-137 downregulates the important transcription
factor MITF and the oncogenes c-Met, YB1, and EZH2, and
thus interferes with multiple crucial signaling pathways in
melanoma development and progression. Because of manifold
interaction of miR-137 with the various signaling pathways,
careful preclinical studies are needed to evaluate what impact
the application of miR-137 would have in vivo and whether
miR-137 might serve as a therapeutic agent or be useful in
combination with other therapies for the treatment of malig-
nant melanoma.
MATERIALS AND METHODS
Patients and cell lines
The melanoma cell lines in this study were established from metastasis of
33 patients with stage III or IV melanoma according to AJCC (Balch et al.,
2001). An institutional approval was obtained for the biopsies from each
participating site with adherence to the Declaration of Helsinki Principles.
Patients provided written, informed consent. For details on characteristics
of patients and cell lines, see Supplementary Table S2 online.
Luciferase reporter assay
Reporter plasmid was cotransfected with miR-137 mimic or negative
control mimic (Dharmacon, Lafayette, CO) into HEK293 cells seeded
in a 96-well plate. Dual luciferase assay was conducted at 48 hours
after transfection according to the manufacturer’s instruction
(Promega, Madison, WI). The Renilla luciferase and firefly luciferase
served as experimental reporter and control reporter, respectively.
The activities of Renilla luciferase and firefly luciferase were mea-
sured, and Renilla/firefly ratios were normalized to the negative
control and further normalized to empty plasmid control. Three
independent experiments were conducted.
Matrigel invasion assay
Invasion assays were performed using Matrigel (10mg matrigel per
well, BD Biosciences, Bedford, MA)-coated 24-well transwell plates
(#3422, Corning Incorporated, Lowell, MA). Briefly, cells at 72 hours
after transfection were seeded into the upper insert with serum-free
medium, and the lower chamber was filled with medium containing
10% fetal calf serum or 10% FSCþ 50 ng ml 1 HGF as chemoat-
tractant. After 24 hours (Ma-Mel-86b) or 48 hours (Ma-Mel-79b), the
noninvaded cells on the upper side of the insert were removed gently
using a cotton swab, and the invaded cells on the lower side of the
insert were stained with crystal violet and photographed under a
microscope. Cells were counted using the ImageJ image analysis
software (National Institutes of Health, Bethesda, MD). Twelve fields
per condition were photographed, and invaded cells were counted
and normalized to negative controls, which were set to 100%.
Alternatively, cells on both sides of the membrane were stained
with Hoechst 33342. The transwell insert was mounted onto a glass
coverslip, which allowed observation of cell nuclei using the Zeiss
Cell Observer inverted microscope (Carl Zeiss, Oberkochen, Ger-
many). Cells on the upper or lower side of the membrane were
distinguished by adjusting focus with a  20 objective. Mosaic
photos of each side were taken and stitched. Cells were counted
using the ImageJ software. The percentage of invaded cells were
calculated and then normalized to the negative control.
Further methods
For plasmid construction, RNA and protein analysis, transfection,
wound healing migration assay, proliferation assay, and statistics see
Supplementary Material online.
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